Chromos Licenses Cellular Engineering Tech to Pfizer
Chromos Molecular Systems said last week that it will non-exclusively license to Pfizer its ACE System to develop cell lines for research, development, and manufacturing of Pfizer products.
The licensing agreement expands upon an original agreement announced in December, under which Chromos is using the ACE System to engineer cell lines to express a Pfizer protein. Pfizer will continue to support this work, Chromos said.
Financial terms of the deal were not disclosed.
Cell Signaling Technology and Chiron Conduct Joint Study
Cell Signaling Technology said last week that it has reached an agreement with Chiron to perform a pilot study using CST's PhosphoScan technology to identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets.
Further terms of the agreement were not disclosed.
NCI Licenses GeneGo's Pathway Analysis Software
GeneGo has licensed its pathway analysis software to the National Cancer Institute, the St. Joseph, Mich.-based company said last week.
Under the agreement, all NCI researchers have access to the 2.5 version of GeneGo's MetaCore software through their web browsers, GeneGo said.
Qiagen and NCI to Develop siRNAs for Cancer Research
Qiagen and the National Cancer Institute will co-develop and validate a set of siRNAs for cancer genes for use by NCI researchers, Qiagen said last week.
The validated siRNA set will be made available to the general research community following the characterization project, Qiagen said.
Financial terms of the deal were not disclosed.